- biOasis has discovered a natural solution to deliver drugs across the blood brain barrier (BBB) using melanotransferrin (MTf), a human protein that transports molecules into the brain. - Their Transcend drug delivery platform uses MTf to link therapeutic compounds to transport medicines for various central nervous system (CNS) diseases that currently have limited treatment options due to the BBB. - Preclinical studies show MTf conjugates significantly increase brain delivery and activity of attached compounds like antibodies, enzymes and chemotherapy drugs.

1. A natural solution
to deliver medicine
to the brain !
biOasis.ca!
OTCQX: BIOAF
TSX.V: BTI
QUARTER 1 !
2015!

2. Forward Looking Statements
Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on
historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”,
“anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially
different from any future results, events or developments express or implied by such forward-looking statements or information.
Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our
intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or
licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results
expressed or implied by such forward-looking statements and information to differ materially from any future events or results
expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs
of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology
companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at
www.sedar.com.
2"
Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this cautionary statement. All forward-
looking statements and information made herein are based on our current expectations and we undertake no
obligation to revise or update such forward- looking statements and information to reflect subsequent events
or circumstances, except as required by law.

3. Central Nervous System Diseases
3"
1) (2012). Brain Facts; A Primer on the Brain and Nervous System . Publication, Society for Neuroscience.
2) (2007). Neurological disorders: Public health challenges . Study, UN World Health Organization .
3) bcc Research . (2010, September ). Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets, PHM068A.
AFFECT 1 IN 6 PEOPLE !
ALL TREATMENTS HINDERED BY THE BLOOD BRAIN BARRIER !
CNS diseases account
for 12% of global
deaths1
Incidence of CNS
diseases will increase by
12% by 20301
Over 1000 different CNS
diseases with drugs
hindered by BBB2
Total cost of CNS
diseases is over $500
billion in USA alone2
CNS disease market is
over $81.2 billion US
and rising3

4. "
Challenge "
The Blood Brain Barrier (“BBB”)
A protective barrier that separates the brain from the
circulatory system, which blocks harmful chemicals from
entering the brain tissue
Problem
The BBB prevents medicines (anti-cancer drugs, enzymes,
antibodies, gene silencing siRNA, etc.) from entering the
brain at levels effective for treatment, blocking about:
• 98% of small molecule drugs
• 100% of large molecule drugs1
Solution
biOasis has discovered a naturally occurring biological
process that can transport drugs across the BBB and into
the brain tissue for the treatment of thousands of CNS
diseases and brain disorders
4"
1) Royal Society of Chemistry
Capillary network of tightly woven endothelial
cells lining the blood vessels in the brain,
regulating transport of essential molecules and
maintaining a stable environment

5. biOasis Presents: The Transcend Program
The Transcend Drug Delivery Platform
5"
Brain Cancers &
Tumours
Metabolic
Diseases like
Lysosomal Storage
Diseases
Neurodegenerative
Diseases like
Alzheimer's Disease
Stroke and
Traumatic Brain
Injury
Gene
Silencing
Therapy
for ALS
Patented carriers that deliver medicines across
the BBB for the treatment of CNS diseases
Transcend offers potential treatments for:
"

6. MTfp (MTf peptide)
• biOasis has discovered the peptide found within the full-
length protein (MTf) that is responsible for transport of MTf
across the BBB
• MTfp has shown improved brain penetration and greater
commercial potential over the full-length MTf protein
Breakthrough Solution
MTf (Melanotransferrin)
• Iron-binding human protein found at low concentrations in
the blood
• When linked to existing drugs, MTf can deliver effective doses
of medicine into the brain, distributing the medicine with a
wide distribution throughout the brain tissue
6"
The Transcend Program
Exploits a natural, biological process to deliver medicines into the brain tissue by linking pre-
existing drugs to a human protein that freely crosses the BBB through receptors located on the
brain capillary wall in a process called Receptor Mediated Transcytosis.

7. Advantage of MTfp
! Higher commercial value over MTf
! More efficient delivery across the BBB
! Lower cost of production
! Greater consistency in manufacturing
! Improved quality control
! Simpler to link to medicines
! Transports a variety of compounds
with no apparent size limitation
! Extends biOasis patent portfolio for
additional ~20 years
! Pharmaceutical collaborators currently
licensing MTfp
7"
RMT!
MTfp in Action
MTfp
Therapeutic
RMT -Receptor
Mediated
Transcytosis
Brain Tissue
Blood Vessels

8. Market Opportunities for Transcend
2014 Drug Market Estimates
8"
A carrier to cross the BBB would establish a
foothold within these major markets
Central Nervous
System
Disorders
!
Stroke &
Traumatic
Brain Injury
Infection
Lysosomal !
Storage
Disease !
~$20
Billion
USD
~$81.2
Billion
USD
~$7.5
Billion
USD
~$2
Billion
USD
~$33.7
Billion
USD
~$138
Billion
USD
~$32.3
Psychiatry
Billion
USD
Neurodegenerative
Disease" Clinical
need met but
improved
BBB
penetration
could
increase
efficacy
Pain &
Migraine
"

9. Brain Cancer Drugs
2013 drug sales for cancers that frequently metastasize in the brain1
9"
1) Company Reported Data
Herceptin® (trastuzumab)
HER2+ Breast Cancer
~40% Metastasize
Taxol® (Paclitaxel)
Lung, ovarian, etc.
~35% Metastasize
Rituxan® (Rituximab)
Blood cancers: lymphoma, leukemia
~24% Metastasize
Erbitux® (Cetuximab) Lung.
colon cancer, etc.
~35% Metastasize
$6.6
Billion
USD
$7.5
Billion
USD
$1.9
Billion
USD
$92
Million
USD
Improved cancer
treatments have
led to an increase
in brain tumours,
creating a need
for anti-cancer
drugs that target
the brain
Anti-cancer
drugs linked to
MTf penetrate
the blood
tumour barrier
10 times more
efficiently
The Transcend
Program has been
shown to reduce
brain tumour
volume by 84%
when anti-cancer
drugs are linked to
MTf

10. Business Opportunities
10"
Patent Cliff
Estimated ~$250 billion in lost
revenue from patent
expirations from 2012-20151
"
1) DeRuiter, J., & Holston, P. L. (2012, June 20). Drug Patent Expirations and the “Patent Cliff”. U.S. Pharm. 2012;37(6)(Generic suppl):12-20.
2) (2007). Neurological disorders: Public health challenges . Study, UN World Health Organization . http://www.un.org/apps/news/story.asp?newsid=21689&cr=neurological#.U7iNnBa4klI
3) (2012). Brain Facts; A Primer on the Brain and Nervous System . Publication, Society for Neuroscience.
Market Growth
CNS Drug Market is the
second largest pharmaceutical
segment behind oncology3
"
Unmet Medical Need
Over 1000 CNS diseases and brain
disorders with treatments hindered
by drug delivery across the BBB2
"
Offers potential patent extensions
to the pharmaceutical industry
through New Chemical Entity
designation for many preexisting,
patent-expiring drugs
Aid in the development of new
therapies and revitalize dormant
candidates that are proven
efficacious but do not cross the
BBB
Expand the CNS drug market by
opening up an industry that has
been heavily stagnated by
ineffective drug delivery to the
brain

11. Management
Board of Directors
Rob Hutchison, Chair & CEO
Former: CEO & Chief Scientist at eCharge Corporation
(One of the world’s first internet banking system)
Chris Fibiger, PhD
Former: Head of Neuroscience, Amgen; VP
Neuroscience, Eli Lily & CSO, Biovail Laboratories
Greg Gubitz, LLB
Former: VP, Biovail Corporation & COO, MDS Capital
Terry Pearson, PhD
Professor: Biochemistry & Microbiology, UVIC
Ron Erickson
Current: Chair & CEO, Visulant Technologies
Michael Hutchison, QC, LLB
Current: Partner, Smith Hutchison Law Corporation
Team
Judi Dalling, LLB, CFO
Seasoned public company CFO and corporate lawyer
Wilfred Jefferies, PhD, Founding Scientist
Discovered MTf’s ability to cross the BBB
Professor: Microbiology & Immunology, UBC
Reinhard Gabathuler, PhD, Chief Scientist
Former: VP Brain Research, Biomarin & CSO,
Angiochem Inc.
Mei Mei Tian, PhD, Scientist
UBC, Microbiology and Immunology (MTf expert)
Laura Ho, MSc, Scientist
UBC, Microbiology and Immunology
Tiffany Tolmie, Corporate Communications
Honours, Wilfrid Laurier University

12. Obtain
independent,
3rd party
validation of
MTf & MTfp
Expand &
protect
intellectual
property
portfolio
Advance
internal
development
programs at
UBC
Collaborate
with reputable
pharmaceutical
companies &
institutions
Corporate Strategy
12"
• Successful delivery of over
12 therapeutic compounds
and over 6 imaging agents
to the brain (enzymes,
antibodies, small molecule
drugs & biological agents)
• Potential to achieve major,
near-term milestones
• Many “shots on goal”
leading to commercial
transactions with
numerous licensees
• Collaborations with large
pharmaceutical partners "
• Over 30 patents granted for
blood-brain barrier drug
delivery and
neurodegenerative
diseases
• Strong pending patent
portfolio
• Over 20 year patent
protection on MTfp
• National Research
Council
• BC Cancer Research
Centre
• Texas Tech University
Health Sciences Center
• Southern Research
Institute
• University of Alabama

13. Strategic Collaborations
The Transcend Program
13"
AbbVie
(Abbott Labs: ABT )
Research Agreement
UCB Pharmaceuticals
(UCB)
Research Agreement
Brains for Brain
Foundation
Research Agreement
MedImmune
(AstraZeneca: AZN)
Licensing Agreement
Ongoing discussions with large
pharmaceutical companies on
licensing and research
agreements.
MTfp
MTf

14. MTf: Rate of Uptake in Brain
14"
Compound
Kin (x10-6;
mL-1/s-1/g-1)
Reference
Glucose
9500
Smith (2003)
Melanotransferrin (MTf)
640
biOasis’ Transcend Program is the only drug delivery platform
that utilizes a natural process to deliver drugs into the brain1
Morphine
200
Cisternino et al. (2001)
Aprotinin
160
Angiochem in Stage 2 Clinical Trials2
Insulin Rec Antibody
100
ArmaGen licensing to Shire (2014)3
Leu-Enkephalin
60
Zlokovic (1987)
Morphine-6-Glucuronide
24
Temsamani et al. (2005)
RAP
10
Raptor Therapeutics – Licensing Issues4
Beta Amyloid
6.5
Banks (1991)
DADLE
6.5
Chen (2002)
TNF-α
4.3
Pan (2002)
TransportEfficiency!
More
Less
Compounds that freely cross the BBB compared to MTf
Competitors
1) Demeule et al. (2002)
2) Demeule et al. (2008)
3) Pardridge (1997)
4) Pan (2004)

15. Development Program: "
biOasis’ MTf + Anti-Aβ antibody
Results
biOasis’ MTf + anti-Aβ antibody conjugate increases
transport into brain tissue by ~5-fold
Quantitative Image Analysis by Laser
Scanning Confocal Microscopy
15"
Alzheimer’s Disease
Anti-Aβ antibodies have
undergone clinical trials for
treatment of Alzheimer’s disease
Opportunity
Using antibodies directed at Aβ
are potential therapeutics for
reducing amyloid plaques in the
brain, which are indicative of
Alzheimer's disease
National Research Council of Canada (NRC)
Anti-Aβ
MTf + Anti-Aβ

16. Development Program:"
biOasis’ MTf + α-L-iduronidase (“IDU”)
Lysosomal Storage Diseases
Rare inherited metabolic diseases caused by an
enzyme deficiency primarily affecting children
Hurler Syndrome (MPS I)
Problem
• MPS I is caused by an IDU enzyme deficiency
• Currently CNS effects untreatable
Results
• biOasis’ MTf + IDU (lysosomal enzyme)
conjugate increased IDU brain enzyme activity
~ 4-fold, showing delivery to the brain tissue
Opportunity
• Offers the promise of an efficient enzyme
replacement therapy
16"
0"
0.2"
0.4"
0.6"
0.8"
1"
1.2"
IDU
MTf - IDU
TotalIDUactivity
Capillaries
Parenchyma
IDU Brain Enzymatic Activity !

17. Development Program:"
biOasis’ MTf + iduronate-2-sulfatase (“IDS”)
Hunters Syndrome (MPS II)
• Lysosomal Storage disease, MPS II is caused
by an IDS enzyme deficiency
• Currently CNS effects untreatable
Results
• biOasis’ MTf + IDS (lysosomal enzyme)
conjugate increased IDS brain enzyme activity
~20-fold, showing delivery to the brain tissue
Opportunity
• Brains for Brain Foundation are in studies with
MTfp + IDS, which offers the opportunity to
fast-track to human trials
• Offers promise of an efficient enzyme
replacement therapy
17"
MTf + IDS Enzyme enters the brain tissue
Native Enzyme does not enter the brain tissue efficaciously

18. Development Program: "
biOasis’ MTf + Doxorubicin
• Doxorubicin is currently used as a cancer
treatment for breast, lung, ovarian, thyroid and
stomach cancers; multiple myeloma, leukemia,
Hodgkin's lymphoma, etc.
Problem
• These cancers metastasize in the brain but
Doxorubicin does not efficiently penetrate the
BBB
Results
• Significant INCREASE in brain uptake with the
MTf + Doxorubicin conjugate vs. Doxorubicin
alone
Opportunity
• MTf + Doxorubicin conjugate could be used to
treat brain cancers that metastasize in the brain
18"
0.00"
1.00"
2.00"
3.00"
MTf + DOXO DOXO
% INJECTED DOSE
(G TISSUE/G BODY MASS)*100%
MTf Significantly Enhances
Doxorubicin Transport into the Brain
Conjugate retains
full activity once
released in the
brain

19. MTf Reduces Doxorubicin Uptake in the Heart
Problem
• Doxorubicin’s most serious adverse
effect is life-threatening heart
damage
Results
• biOasis’ MTf + Doxorubicin vs.
Doxorubicin on its own showed a
significant DECREASE in uptake in
the heart
Opportunity
• Could be used to treat brain
cancers and decrease heart-uptake
side effect, offering increased
usage of Doxorubicin for brain
cancer treatment
19"
0.0"
5.0"
10.0"
15.0"
20.0"
%INJECTEDDOSE
(grambraintissue/grambodymass)*100
MTf + DOXO DOXO

20. Development Program: "
biOasis’ MTf + Trastuzumab (Herceptin®)
• Trastuzumab (Herceptin®)1 is a humanized
monoclonal antibody used to treat HER2+
breast cancer with annual global sales ~$6.6
billion2
• Herceptin® increases survival rate but ~40%
of patients eventually develop breast cancer
metastasis in the brain3
• Trastuzumab (Herceptin®) does not cross the
BBB on its own
• biOasis aims to, not only prevent and treat
HER2+ breast cancer that metastasizes in the
brain, but also for Transcend to become the
‘Standard of Care’ for HER2+ breast cancer
20"
1) Herceptin® is a registered trademark of Roche/Genentech
2) Company Reported Data – 2013
3) Britta Weigelt, Johannes L. Peterse & Laura J. van't Veer. (2005, August). Breast cancer metastasis: markers and models. Nature Reviews
Cancer 5 , 591-602.
Brain Capillaries
Cell Nuclei
MTf + Trastuzumab (Herceptin®)
Confocal Image Performed by iCapture at
St. Paul’s Hospital Vancouver Canada
MTf + Trastuzumab (Herceptin®)
Confocal Images Two Hours Post IV Administration

21. MTf + Trastuzumab (Herceptin®) "
Texas Tech University - Breast Cancer Model
21"
0"
10"
20"
30"
40"
50"
60"
70"
80"
90"
MTf TZM MTf-TZM Saline
Control !
Number of Tumours
Highlights
• Reduced the number of HER2+ breast
cancer tumours in the brain by 68%
• Total tumor volume reduced by 84% in
only 14 days, after 4 treatments
• Penetrated the Blood-Tumour Barrier
10 times better than Herceptin® alone
• Increased cancer killing effect of
Herceptin® in tumours throughout the
body when linked with MTf
• Offers the potential to be used in
conjunction with HER2+ cancer
therapy as a treatment and
preventative measure BEFORE the
cancer metastasizes to the brain
68%
Reduction
TZM = Trastuzumab (Herceptin®)

22. Development Program: "
MTfp + siRNA
Small Interfering RNA (siRNA)
• Silences target gene expression by knocking down disease
causing genes associated with human diseases
(i.e. cancers, neurodegenerative and metabolic diseases, etc.)
Problem
• Gene targeting within the brain is currently unachievable because
siRNA does not cross the BBB
Results
• MTfp + siRNA conjugate delivered into the brain tissue
• Demonstrated 40% to 50% decrease in target gene vs. siRNA
alone
Opportunity
• A potential cornerstone technology for the development of new
therapeutics suppressing disease-linked genes in the brain
• siRNA is a rapidly emerging field of medicine
22"
National Research Council
NO siRNA detected in Brain
MTf + siRNA detected in Brain

23. Pipeline
23"
Brain
Transport
Quantity in
the Brain
Localization in
Brain (Cellular)
Efficacy
Models
Brain Cancer
Herceptin: Breast Cancer
Lysosomal Storage Disease
Hunters Syndrome: MPS II Model
Sandhoff Disease: Hex B Model
siRNA
Stroke Model A
ALS Model B

24. Market Profile "
24"
Data source: S&P Capital IQ
TSX.V:BTI; OTCQX:BIOAF
Shares Issued & Outstanding
44,034,257
Fully Diluted
52,073,734
Options
6,095,000
Directors, officers & employees
Warrants
1,944,477
IP Warrants
Market Cap
~$52.8m
@ $1.20 Share Price (Feb. 2, 2015)
Cash Position
~$2,095,329
Ownership
Insiders & Affiliates ~35%
Institutional ~10%

25. Summary
25"
!
Intellectual
Property
& Collaborations
Strong patent protection
Patent portfolio of >30 patents
Large pharmaceutical
collaborations
Positive results;
successful demonstration
Large Market
Opportunities
Ability to extend patent life
Commercialize new therapeutics
and/or revitalize dormant
candidates
Contribute to the growth
in CNS drug market
"
Treatment
Potential
Metabolic diseases
Neurodegenerative
diseases
Brain Cancer
"
Awarded TSX.V Top
50® in 2013
Leader in providing shareholder value
Market Profile
Good cash position
Clean share structure
Exit strategy in place
High internal
ownership
Management
Major success in:
Drug commercialization
Biotechnology & venture
capital startups
Academia
"
Transcend
Program
“The first natural
carrier to effectively
transport therapeutic
drugs into the brain.”
Discovery
of MTfp
Enhanced technology
Greater commercial
potential
"